Exploring a Partnership : Novel HDO Therapeutics

We are a biotechnology company specializing in next-generation RNA therapeutics and delivery systems. We would like to request a meeting with your team to explore potential collaboration opportunities.

Our proprietary platform is based on Heteroduplex Oligonucleotides (HDOs), a novel double-stranded oligonucleotide technology. This platform enables both RNase H-dependent gene knockdown and RNase H-independent steric-blocking effects, such as exon skipping and anti-miR activity.

Importantly, our HDOs exhibit superior nuclear uptake compared to traditional single-stranded antisense oligonucleotides, thereby driving enhanced pharmacological effects.

We are actively pursuing strategic partnerships for out-licensing, co-development, or target-specific collaborations in fields where our oligonucleotide and delivery platforms can deliver substantial value. Our primary focus lies in rare diseases, genetic disorders, and organ-targeted RNA therapies.

We would be delighted to share our latest findings with you and discuss how our technologies might align with your pipeline. Thank you for your time and consideration, and we look forward to the possibility of connecting